Evidence map›Paper›PMID 38204235›Full record

ArticleCurrent pharmaceutical biotechnology2024

Immunohistochemical Expression of the SERPINA3 Protein in Uterine Fibroids.

Mateusz de Mezer, Anna Markowska, Janina Markowska, Monika Krzyżaniak, Beniamin Oskar Grabarek, Filip Pokusa, Jakub Żurawski

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mateusz de MezerDepartment of Immunobiology, Chair of Medical Biology, Poznan University of Medical Sciences, Poznan, Poland.
Anna MarkowskaDepartment of Perinatology and Women's Diseases, Poznan University of Medical Sciences, Poznan, Poland.
Janina MarkowskaGynecological Center, Poznan, Poland.
Monika KrzyżaniakDepartment of Oncological Pathology, Lord's Transfiguration Clinical Hospital, Partner of Poznan University of Medical Sciences, Poznan, Poland.
Beniamin Oskar GrabarekCollegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland.
Filip PokusaFaculty of Economics and Pedagogy, Higher School of Management and Administration in Opole, 46-020 Opole, Poland.
Jakub ŻurawskiDepartment of Immunobiology, Chair of Medical Biology, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSERPINA3 (α-1-antichymotrypsin, AACT, ACT) is produced by the liver and released into plasma in an anti-inflammatory response and plays a role as a modulator of extracellular matrix (ECM) by inhibiting serine proteases. Numerous studies proved an increased level of SERPINA3 in many types of cancer, which could be linked to SERPINA3's anti-apoptotic function.

aimIn the context of progressive ECM fibrosis during the development of uterine fibroids, which are one of the most common hypertrophic changes within the uterus, it is interesting to describe the level of SERPINA3 protein in this type of lesion and the surrounding tissues.

methodsWe used immunohistochemical staining of the SERPINA3 protein and compared the intensity of the signal between the myoma tissue and the surrounding normal tissue.

resultsWe showed a surprising reduction in the amount of the SERPINA3 protein within uterine fibroids compared to surrounding tissues.

conclusionThis observation sheds new light on the role of this protein in the formation of proliferative changes and suggests that understanding the mechanism of its action may become the basis for the development of new diagnostic and therapeutic tools.

Indexed as

ImmunohistochemistryLeiomyomaSerpinsUterine NeoplasmsAdultFemaleHumansMiddle AgedUterusSERPINA3 protein, humanSerpinsACT)complications in childbirth.extracellular matrix (ECM)monoclonal tumorsmyomaSERPINA3uterine fibroidsα-1-antichymotrypsin (AACT

Identifiers

PMID38204235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.